Glycoproteïne-IIb/IIIa-antagonisten. Veel studies, weinig antwoorden

Translated title of the contribution: Many studies, few answers. Glycoprotein IIb/IIIa receptor inhibitors

P. M. Bet, J. J.W. Ros, A. C. Van Loenen

Research output: Contribution to journalArticleAcademicpeer-review


In this article we present an update on the pharmacokinetic, pharmacodynamic and clinical studies of the parenteral glycoprotein IIb/IIIa receptor inhibitors available in the Netherlands. These are abciximab (Reopro®), eptifibatide (Integreline®) and tirofiban (Aggrastat®). Glycoprotein IIb/IIIa receptor inhibitors appear to be effective only in combination with percutaneous coronary interventions. The application of glycoprotein IIb/IIIa receptor inhibitors without percutaneous coronary interventions has limited value. Glycoprotein IIb/IIIa receptor inhibitors remain less effective than expected on theoretical grounds. Lots of studies have been performed with inconclusive results. Therefore little answers are available.

Translated title of the contributionMany studies, few answers. Glycoprotein IIb/IIIa receptor inhibitors
Original languageDutch
Pages (from-to)746-750
Number of pages5
JournalPharmaceutisch Weekblad
Issue number21
Publication statusPublished - 23 May 2003


  • Abciximab
  • Angioplasty, transluminal, percutaneous coronary
  • Eptifibatide
  • Glycoprotein IIb/IIIa receptor inhibitors
  • Myocardial ischemia
  • Tirofiban

Cite this